Skip to main navigation

Skip links

Skip to content
Skip to footer

Akari TX

Main navigation

Menu

HOME
ABOUT
- Close
- MANAGEMENT
- BOARD OF DIRECTORS
LEAD INDICATIONS
- Close
- OVERVIEW
- PNH PHASE II/III
- ECULIZUMAB-RESISTANT PHASE II
- LONG TERM SAFETY
- BULLOUS PEMPHIGOID PHASE IIA
- AKC PHASE I/II
- PRECLINICAL PROGRAMS
  - Close
  - NOMACOPAN LA
  - OTHER INDICATIONS
THE SCIENCE
- Close
- OVERVIEW
- MODE OF ACTION
- TARGET DISEASES
  - Close
  - PNH
  - ECULIZUMAB RESISTANCE
  - BULLOUS PEMPHIGOID
  - AKC
- TARGET PATHWAYS
  - Close
  - C5 (COMPLEMENT SYSTEM)
  - LTB4 (LEUKOTRINE SYSTEM)
- MOLECULES
INVESTOR RELATIONS
- Close
- OVERVIEW
- FINANCIAL INFORMATION
  - Close
  - SEC FILINGS
  - ANNUAL REPORTS
- NEWS & EVENTS
  - Close
  - PRESS RELEASES
  - EVENTS
  - PRESENTATIONS
- STOCK INFORMATION
  - Close
  - STOCK QUOTE & CHART
  - HISTORIC PRICE LOOKUP
  - INVESTMENT CALCULATOR
- CORPORATE GOVERNANCE
  - Close
  - GOVERNANCE OVERVIEW
  - BOARD OF DIRECTORS
  - MANAGEMENT
  - COMMITTEE COMPOSITION
- INVESTOR RESOURCES
  - Close
  - INVESTOR FAQS
  - EMAIL ALERTS
PRESS
- Close
- PRESS RELEASES
- PUBLICATIONS
CONTACT US

Events

Akari Therapeutics at the LEERINK Partners 7th Annual Global Healthcare Conference

February 15, 2018 at 11:00 AM EST

Click here for webcast

Print Page
Email Alerts
RSS Feeds
Contact Us

Footer

LONDON

75/76 Wimpole Street London W1G 9RT UK

T: +44 (0)20.8004.0261
E: info@Akaritx.com

NEW YORK

135 W 41st Street. 5th Floor New York, NY, 10036

T: 929.274.7510
F: 646.843.9352
E: info@Akaritx.com

Copyright © 2020 Akari Therapeutics Plc. All rights reserved.